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the introduction of PCV7, net costs averted are in the range of $5 million as a result 
of the implementation of PCV7 universal vaccination in Alberta. Over the time 
period, direct protection resulted in net cost savings of $2.6 million, and indirect 
benefits $2.4 million; the indirect benefits derived by elderly populations were more 
than one third of the total benefits derived across the population. ConClusions: 
This study is unique in that it uses validated surveillance data from Alberta to 
retrospectively assess the economic benefit of a public health policy, and describes 
the distribution of benefits across different segments of the population. From 2003 
to 2008, the cumulative cost impact of introducing PCV7 in the childhood immu-
nization program to the Alberta health system is approximately $5 million, half of 
which were a result of herd immunity.
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objeCtives: In pharmaceutical comparative effectiveness studies, patients fre-
quently discontinue drug treatments soon after initiation, potentially biasing esti-
mated costs attributed to treatments. A partitioned data structure may facilitate 
estimating costs in the presence of censoring. We compared health care utilization 
costs for two chronic obstructive pulmonary disease (COPD) treatments over a one-
year period using intent-to-treat (ITT) and as protocol (AP) approaches. Methods: 
Claims data from two managed care health plans from July 2004 through September 
2013 was used to compare annual health care costs for COPD patients treated with 
1) inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) or long-acting mus-
carinic antagonist (LAMA) (non-triple) therapy, or 2) concurrent ICS/LABA+LAMA 
(triple) therapy. Post-treatment costs were aggregated by 4-week periods. Costs were 
estimated for ITT and AP treatment groups, using actual and weighted cost methods. 
Patients were censored for health plan disenrollment (possible after 6 months post-
index). In the AP analysis, patients were additionally censored for discontinuation of 
treatment. Weights were the inverse probability of remaining uncensored. Results: 
Study subjects numbered 5,475; 484 triple, 4,991 non-triple. Few patients disenrolled 
(n= 139) by one-year post-index. ITT cost estimates were similar for actual and 
weighted cost methods. ITT actual mean total costs were significantly higher for 
triple therapy patients (P= 0.01): $20,013 (standard deviation [SD], $12,865) for triple, 
and $18,468 (SD, $11,619) for non-triple. Censoring was heavy in the AP analysis. 
Probability for remaining uncensored during the 13th four-week period was 28.5% 
for triple patients and 22% for non-triple patients. AP actual mean total costs were 
considerably lower than ITT costs: $12,586 (SD, $9,991) for triple therapy, $8,688 (SD, 
$7,896) for ICS/LABA or LAMA. AP weighted mean total costs were $19,133 for triple 
therapy and $16,814 for non-triple. ConClusions: The weighted method allowed 
censored individuals to contribute cost information. AP analysis costs were lower 
than ITT costs, highlighting the impact of therapy discontinuation on analyses.
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objeCtives: The prevalence of COPD is higher and increases every year in China. 
To estimate hospital inpatient costs, LOS and complication among patients with 
osteoporosis fractures in China. Methods: Data were extracted by the discharge 
diagnosis of COPD from the China Health Insurance Research Association claim 
database which includes a nationwide, cross-sectional sampling of inpatients’ visits 
in 2011. Several complications were chosen from reference to our objective compli-
cation, the inpatients’ visits with these complication were chosen by their diagnosis 
and drug used because the records were not integrity. The descriptive analysis of 
LOS, total medical costs and other parameters were calculated. Continuous vari-
ables were examined by student’s t test for we showed all results with mean value 
and standard deviation. The statistical software was SPSS. Results: The analysis 
included 8667 hospitalizations (Male: 62.71%, Age: 72.08±74 years). Overall LOS and 
costs were 16.17±25.70 days and 7949.59±11782.33 RMB. Sample of hospitalization 
with complication of heart failure was most ( 2503 ), followed by atrial fibrilla-
tion (AF), diabetes mellitus (DM), hypertension, osteoporosis, ischemic heart 
disease(IHD). While, patients with osteoporosis had the most hospitalization 
cost (17352.85±29584.08 RMB), followed by IHD (17140.08±25472.15 RMB), anxiety-
depression (16399.81±22671.54 RMB), DM (13709.27±22288.66 RMB) and hyper-
tension (13564.59±20725.80 RMB). For hospitalization cost, Men’s was more than 
women’s (8366.42 ±11034.93 vs. 7248.65 ±12913.71 RMB p< 0.05), employee’s was more 
than residents’ (9126.86±13026.41 vs. 4887.81 ±6753.29 RMB p< 0.001), inpatients’ 
(age over than 80 ) was the most (9697.75±12238.17, RMB p< 0.001), east’s was the 
most(10853.62±14751.43 RMB p< 0.001), prefecture-level city’s was the most(8039.55 
±14584.93 RMB 0.05< p< 0. 1). ConClusions: Heart failure was a common com-
plication among COPD patients, and osteoporosis increased the hospitalization 
cost for COPD patients which might be for the surgery. Hospitalization cost varied 
significantly among different patients and area, expect different level of city. The 
relationship between cost and complication should be studied further in future.
PRS26
SyStematiC RevieW of eConomiC BuRden in SymPtomatiC ChRoniC 
oBStRuCtive PulmonaRy diSeaSe (CoPd) PatientS
Srivastava K.1, Thakur D.1, Sharma S.1, Punekar Y.S.2
1HERON Health Pvt. Ltd., Chandigarh, India, 2GlaxoSmithKline, Uxbridge, UK
objeCtives: To systematically assess the global economic burden associated with 
symptomatic COPD. Methods: A systematic search of Embase®, MEDLINE®, 
EconLit® and LILACS® was conducted for last 10 years along with search of con-
ference proceedings for last 3 years. Non-randomised trials and observational stud-
infection, MXN$123 million for pneumococcal diseases, MXN$199 million for HPV, 
and MXN$258 million for B. pertussis. Cost offsets in Year 1 after adoption of the 
immunization program totaled MXN$23 million for RSV infection, MXN$38 million 
for pneumococcal diseases, MXN$133 million for HPV, and MXN$206 million for 
B. pertussis. ConClusions: This model suggests that targeting RSV prophylaxis 
to high-risk populations can lead to substantial cost offsets, which are consistent 
with or improve on the budget impact of other preventive health programs for 
childhood diseases in Mexico.
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objeCtives: Arformoterol tartrate inhalation solution (arformoterol) is a long-act-
ing beta2-agonist indicated for long-term maintenance treatment of bronchocon-
striction in patients with chronic obstructive pulmonary disease (COPD). Nebulized 
albuterol (albuterol) is a short acting beta-agonist indicated as rescue medication 
for acute COPD exacerbations, but often patients receive it in place of maintenance 
treatment. This analysis estimated total medical, pharmacy and rehospitalization 
costs for nebulized arformoterol compared with albuterol nebulized solution for 
the management of COPD in hospitalized patients. Methods: An economic model 
was built comparing health care resource utilization and rehospitalization costs 
for arformoterol and albuterol from the hospital perspective. Pharmacy costs were 
calculated on a cost per hospital stay basis and were determined by the number 
of doses, frequency of administration, and hospital length of stay (LOS). Pharmacy 
costs were based on publically available wholesale acquisition costs. Medical costs 
included COPD exacerbation hospitalization costs, rehospitalization costs, and 
respiratory therapy costs. Cost of COPD-related inpatient hospitalizations were 
calculated as the cost per day times the mean LOS. Rehospitalization costs were 
calculated using rehospitalization rates at 30, 90, and 180 days. Respiratory ther-
apy costs were based on the number of daily sessions for administration and the 
hourly rate of respiratory therapy. Results: Mean LOS was 4.4 days for arformoterol 
vs. 5.2 days for albuterol. Arformoterol had lower rates of rehospitalization at 30, 
90 and 180 days post-discharge, respectively (8.7% vs. 11.9%, 15.4% vs. 26.8% and 
31.7% vs. 38.2%). Total medical and pharmacy costs per treated patient for arfor-
moterol were $6,953 vs. $8,456 for albuterol, resulting in a savings of $1,503 per 
patient. Arformoterol yielded net savings of $338, $1,025, and $847 over albuterol 
in rehospitalization cost per treated patient at 30, 90 and 180 days, respectively. 
ConCluSionS: Total costs of arformoterol were less than albuterol nebulized solu-
tion due to lower hospitalization and rehospitalization costs.
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objeCtives: To estimate the economic burden of lost productivity and health care 
resource use associated to tobacco in the Brazilian population among smoking 
and non-smoking/ex-smoking employees. Methods: A structured search was 
performed on MEDLINE database (via PubMed) using the MesH Database terms 
in accordance with the following terms ((“Costs and Cost Analysis” [Mesh]) AND 
(“Smoking” [Mesh]) AND (“ absenteeism” [Mesh]) AND (“presenteeism” [Mesh])), 
as well as the cost of absence days due to health events retrieved from national 
labor legislations; and average wage was retrieved from the Brazilian Institute for 
Geography and Statistics (IBGE) 2.013. Results: The disease costs related to tobacco 
are Cardiovascular disease (CVD) BRL 27,845.32; stroke BRL 20,591.24; Chronic 
obstructive pulmonary disease (COPD) BRL 21,328.59; pneumonia BRL 1,111.82; lung 
cancer BRL 67,225.83; other cancers BRL 85,524.46. When comparing the productivity 
and absence days, the smokers lose 62.1% more days than nonsmokers and 41.34% 
than ex-smokers, which corresponds to BRL 1,326.62 in terms of annual monetary 
average cost. Additionally, it was found that the life expectancy of male smokers 
corresponds to 75.30 years; for females, it already was 79.77 years. That means a 
loss of 5.03 and 4.5 years, respectively, when compared to the expected useful lives 
of the the nonsmoking population. ConClusions: Therefore, smoking employees 
can cost, on unproductive days, almost 3 times more than non-smokers and 2 times 
more than ex-smokers, besides the cost related to the treatment of stroke, COPD 
and CVD, and others.
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objeCtives: Acute respiratory tract infections caused by Streptococcus pneumoniae(SP) 
are a leading cause of morbidity and mortality in young children and the elderly. 
In 2002, Alberta introduced a pneumococcal universal immunization program for 
children, using Prevnar 7 (PCV7). In this study, we assess the economic impact of 
PCV7 on the Alberta health care system. Methods: Using active surveillance data 
from Alberta, we examine the net costs averted as a result of a decline in PCV7 
serotypes, accounting for the increase in costs due to serotype replacement. We 
also calculate the magnitude of herd immunity in terms of costs averted. Results: 
We find that following the introduction of PCV7 (2003-2008), the number of cases 
of invasive disease caused by vaccine serotypes declined significantly across all 
ages. Specifically, by 2008, there was considerable evidence of herd immunity as 
the incidence rates had declined nearly 100% across all ages. However, non-PCV7 
cases, on the other hand, increased. Assuming serotype replacement is a result of 
